JP2015505829A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505829A5 JP2015505829A5 JP2014544867A JP2014544867A JP2015505829A5 JP 2015505829 A5 JP2015505829 A5 JP 2015505829A5 JP 2014544867 A JP2014544867 A JP 2014544867A JP 2014544867 A JP2014544867 A JP 2014544867A JP 2015505829 A5 JP2015505829 A5 JP 2015505829A5
- Authority
- JP
- Japan
- Prior art keywords
- tissue
- ischemia
- cells
- stem
- progenitor cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000130 stem cell Anatomy 0.000 claims description 276
- 210000001519 tissue Anatomy 0.000 claims description 86
- -1 Desoxycorton Chemical compound 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 45
- 208000028867 ischemia Diseases 0.000 claims description 43
- 230000000302 ischemic effect Effects 0.000 claims description 42
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 40
- 230000014509 gene expression Effects 0.000 claims description 39
- 102000008186 Collagen Human genes 0.000 claims description 35
- 108010035532 Collagen Proteins 0.000 claims description 35
- 102000004134 Fos-related antigen 2 Human genes 0.000 claims description 35
- 108090000641 Fos-related antigen 2 Proteins 0.000 claims description 35
- 102100025626 GTP-binding protein GEM Human genes 0.000 claims description 35
- 102000003918 Hyaluronan Synthases Human genes 0.000 claims description 35
- 108090000320 Hyaluronan Synthases Proteins 0.000 claims description 35
- 102100028255 Renin Human genes 0.000 claims description 35
- 108090000783 Renin Proteins 0.000 claims description 35
- 229920001436 collagen Polymers 0.000 claims description 35
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 32
- 102100027085 Dual specificity protein phosphatase 4 Human genes 0.000 claims description 28
- 101001057621 Homo sapiens Dual specificity protein phosphatase 4 Proteins 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 150000003180 prostaglandins Chemical class 0.000 claims description 23
- 239000003862 glucocorticoid Substances 0.000 claims description 22
- 101000856606 Homo sapiens GTP-binding protein GEM Proteins 0.000 claims description 21
- 239000000556 agonist Substances 0.000 claims description 21
- 230000037361 pathway Effects 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 18
- 229960000890 hydrocortisone Drugs 0.000 claims description 16
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 11
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims description 11
- 230000005012 migration Effects 0.000 claims description 11
- 238000013508 migration Methods 0.000 claims description 11
- 238000010232 migration assay Methods 0.000 claims description 11
- 208000031225 myocardial ischemia Diseases 0.000 claims description 10
- 229960003957 dexamethasone Drugs 0.000 claims description 9
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 9
- 206010034576 Peripheral ischaemia Diseases 0.000 claims description 8
- 108091027981 Response element Proteins 0.000 claims description 8
- 206010008118 cerebral infarction Diseases 0.000 claims description 8
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims description 7
- 101150066398 CXCR4 gene Proteins 0.000 claims description 7
- 101710116158 GTP-binding protein GEM Proteins 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 229960004584 methylprednisolone Drugs 0.000 claims description 7
- 108020004017 nuclear receptors Proteins 0.000 claims description 7
- 108010008370 protein phosphatase 4 Proteins 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 229960005294 triamcinolone Drugs 0.000 claims description 7
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 7
- 201000006474 Brain Ischemia Diseases 0.000 claims description 6
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 6
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 claims description 6
- 206010021143 Hypoxia Diseases 0.000 claims description 6
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 6
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 6
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 208000029078 coronary artery disease Diseases 0.000 claims description 6
- 235000015110 jellies Nutrition 0.000 claims description 6
- 239000008274 jelly Substances 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 6
- 208000019553 vascular disease Diseases 0.000 claims description 6
- 208000030175 lameness Diseases 0.000 claims description 5
- 201000002818 limb ischemia Diseases 0.000 claims description 5
- 230000029663 wound healing Effects 0.000 claims description 5
- QAOBBBBDJSWHMU-WMBBNPMCSA-N 16,16-dimethylprostaglandin E2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O QAOBBBBDJSWHMU-WMBBNPMCSA-N 0.000 claims description 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- 208000010392 Bone Fractures Diseases 0.000 claims description 4
- 206010017076 Fracture Diseases 0.000 claims description 4
- 206010022680 Intestinal ischaemia Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 4
- 206010052428 Wound Diseases 0.000 claims description 4
- 206010069351 acute lung injury Diseases 0.000 claims description 4
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 230000002490 cerebral effect Effects 0.000 claims description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 229960002842 clobetasol Drugs 0.000 claims description 4
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims description 4
- 230000003111 delayed effect Effects 0.000 claims description 4
- 229960002593 desoximetasone Drugs 0.000 claims description 4
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 210000003981 ectoderm Anatomy 0.000 claims description 4
- 230000003511 endothelial effect Effects 0.000 claims description 4
- 210000004700 fetal blood Anatomy 0.000 claims description 4
- 229960003469 flumetasone Drugs 0.000 claims description 4
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 claims description 4
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims description 4
- XWTIDFOGTCVGQB-FHIVUSPVSA-N fluocortin butyl Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(=O)OCCCC)[C@@]2(C)C[C@@H]1O XWTIDFOGTCVGQB-FHIVUSPVSA-N 0.000 claims description 4
- 229960002650 fluprednidene acetate Drugs 0.000 claims description 4
- DEFOZIFYUBUHHU-IYQKUMFPSA-N fluprednidene acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC(=C)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O DEFOZIFYUBUHHU-IYQKUMFPSA-N 0.000 claims description 4
- 230000007954 hypoxia Effects 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 4
- 229960001293 methylprednisolone acetate Drugs 0.000 claims description 4
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 210000002826 placenta Anatomy 0.000 claims description 4
- 210000002435 tendon Anatomy 0.000 claims description 4
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 4
- 210000003954 umbilical cord Anatomy 0.000 claims description 4
- 206010010904 Convulsion Diseases 0.000 claims description 3
- 206010017711 Gangrene Diseases 0.000 claims description 3
- 208000004044 Hypesthesia Diseases 0.000 claims description 3
- 206010040829 Skin discolouration Diseases 0.000 claims description 3
- 230000036461 convulsion Effects 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000034783 hypoesthesia Diseases 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 3
- 231100000862 numbness Toxicity 0.000 claims description 3
- 230000037370 skin discoloration Effects 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- VHRSUDSXCMQTMA-UHFFFAOYSA-N 11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound CC12C=CC(=O)C=C1C(C)CC1C2C(O)CC2(C)C(O)(C(=O)CO)CCC21 VHRSUDSXCMQTMA-UHFFFAOYSA-N 0.000 claims description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 2
- MYYIMZRZXIQBGI-HVIRSNARSA-N 6alpha-Fluoroprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 claims description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 206010002660 Anoxia Diseases 0.000 claims description 2
- 241000976983 Anoxia Species 0.000 claims description 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 2
- 208000017234 Bone cyst Diseases 0.000 claims description 2
- 208000014644 Brain disease Diseases 0.000 claims description 2
- 206010048962 Brain oedema Diseases 0.000 claims description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
- 208000033386 Buerger disease Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010007710 Cartilage injury Diseases 0.000 claims description 2
- 206010065384 Cerebral hypoperfusion Diseases 0.000 claims description 2
- 206010061762 Chondropathy Diseases 0.000 claims description 2
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000034656 Contusions Diseases 0.000 claims description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 claims description 2
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 claims description 2
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 claims description 2
- 208000001034 Frostbite Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 206010058490 Hyperoxia Diseases 0.000 claims description 2
- 208000013016 Hypoglycemia Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010022562 Intermittent claudication Diseases 0.000 claims description 2
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 claims description 2
- 208000034693 Laceration Diseases 0.000 claims description 2
- 206010028851 Necrosis Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000037581 Persistent Infection Diseases 0.000 claims description 2
- 229940121820 Prostaglandin EP2 receptor agonist Drugs 0.000 claims description 2
- 229940123028 Prostaglandin EP4 receptor agonist Drugs 0.000 claims description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 2
- 206010063897 Renal ischaemia Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010040943 Skin Ulcer Diseases 0.000 claims description 2
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010047249 Venous thrombosis Diseases 0.000 claims description 2
- DERCOWNWEPPIHD-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2O DERCOWNWEPPIHD-UHFFFAOYSA-N 0.000 claims description 2
- 230000007953 anoxia Effects 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 229950000210 beclometasone dipropionate Drugs 0.000 claims description 2
- 229940092705 beclomethasone Drugs 0.000 claims description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 2
- 229960002537 betamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 2
- SOQJPQZCPBDOMF-YCUXZELOSA-N betamethasone benzoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@@H]1C)C(=O)CO)C(=O)C1=CC=CC=C1 SOQJPQZCPBDOMF-YCUXZELOSA-N 0.000 claims description 2
- 229960000870 betamethasone benzoate Drugs 0.000 claims description 2
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims description 2
- 229960004311 betamethasone valerate Drugs 0.000 claims description 2
- 210000005068 bladder tissue Anatomy 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 230000017531 blood circulation Effects 0.000 claims description 2
- 208000006752 brain edema Diseases 0.000 claims description 2
- 210000005013 brain tissue Anatomy 0.000 claims description 2
- CQFNOACVVKSEOJ-VBQPQCOESA-N bronilide Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O CQFNOACVVKSEOJ-VBQPQCOESA-N 0.000 claims description 2
- 229960004436 budesonide Drugs 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 210000000845 cartilage Anatomy 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 201000005483 chronic intestinal vascular insufficiency Diseases 0.000 claims description 2
- 229960003728 ciclesonide Drugs 0.000 claims description 2
- 210000002808 connective tissue Anatomy 0.000 claims description 2
- 230000009519 contusion Effects 0.000 claims description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims description 2
- 229960004544 cortisone Drugs 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 229960003662 desonide Drugs 0.000 claims description 2
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 claims description 2
- 229960004875 difluprednate Drugs 0.000 claims description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000003073 embolic effect Effects 0.000 claims description 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 2
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 claims description 2
- 229960004511 fludroxycortide Drugs 0.000 claims description 2
- 229940042902 flumethasone pivalate Drugs 0.000 claims description 2
- JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 claims description 2
- 229960000676 flunisolide Drugs 0.000 claims description 2
- 229960000442 flunisolide hemihydrate Drugs 0.000 claims description 2
- 229940043075 fluocinolone Drugs 0.000 claims description 2
- 229960001347 fluocinolone acetonide Drugs 0.000 claims description 2
- 229960000785 fluocinonide Drugs 0.000 claims description 2
- 229960005355 fluocortin Drugs 0.000 claims description 2
- 229950008509 fluocortin butyl Drugs 0.000 claims description 2
- 229960001048 fluorometholone Drugs 0.000 claims description 2
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 claims description 2
- 229960003590 fluperolone Drugs 0.000 claims description 2
- HHPZZKDXAFJLOH-QZIXMDIESA-N fluperolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](OC(C)=O)C)(O)[C@@]1(C)C[C@@H]2O HHPZZKDXAFJLOH-QZIXMDIESA-N 0.000 claims description 2
- 229960000618 fluprednisolone Drugs 0.000 claims description 2
- 229960002714 fluticasone Drugs 0.000 claims description 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 2
- 229960000289 fluticasone propionate Drugs 0.000 claims description 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 2
- 229960002475 halometasone Drugs 0.000 claims description 2
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 claims description 2
- 230000035876 healing Effects 0.000 claims description 2
- 229960001067 hydrocortisone acetate Drugs 0.000 claims description 2
- 230000000222 hyperoxic effect Effects 0.000 claims description 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 210000005228 liver tissue Anatomy 0.000 claims description 2
- 229960001798 loteprednol Drugs 0.000 claims description 2
- YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 claims description 2
- 210000003141 lower extremity Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 229960001664 mometasone Drugs 0.000 claims description 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 2
- 229960002744 mometasone furoate Drugs 0.000 claims description 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 2
- 229960004123 mometasone furoate monohydrate Drugs 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 230000017074 necrotic cell death Effects 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 210000004923 pancreatic tissue Anatomy 0.000 claims description 2
- 210000004738 parenchymal cell Anatomy 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 230000003169 placental effect Effects 0.000 claims description 2
- 210000004991 placental stem cell Anatomy 0.000 claims description 2
- 229960002794 prednicarbate Drugs 0.000 claims description 2
- FNPXMHRZILFCKX-KAJVQRHHSA-N prednicarbate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O FNPXMHRZILFCKX-KAJVQRHHSA-N 0.000 claims description 2
- 229960005205 prednisolone Drugs 0.000 claims description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 208000005333 pulmonary edema Diseases 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 238000007634 remodeling Methods 0.000 claims description 2
- 210000005084 renal tissue Anatomy 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- 208000032253 retinal ischemia Diseases 0.000 claims description 2
- 210000002027 skeletal muscle Anatomy 0.000 claims description 2
- 231100000019 skin ulcer Toxicity 0.000 claims description 2
- 210000002460 smooth muscle Anatomy 0.000 claims description 2
- 210000000278 spinal cord Anatomy 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 2
- 230000001732 thrombotic effect Effects 0.000 claims description 2
- 208000037816 tissue injury Diseases 0.000 claims description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 229940070710 valerate Drugs 0.000 claims description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 1
- 230000000919 anti-host Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 210000003414 extremity Anatomy 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 208000021267 infertility disease Diseases 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- 230000008736 traumatic injury Effects 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 109
- 102000012000 CXCR4 Receptors Human genes 0.000 description 31
- 108010061299 CXCR4 Receptors Proteins 0.000 description 31
- 102000007299 Amphiregulin Human genes 0.000 description 29
- 108010033760 Amphiregulin Proteins 0.000 description 29
- 102000006255 nuclear receptors Human genes 0.000 description 6
- 208000035824 paresthesia Diseases 0.000 description 2
- 208000028048 Accommodation disease Diseases 0.000 description 1
- 108091008928 CXC chemokine receptors Proteins 0.000 description 1
- 102000054900 CXCR Receptors Human genes 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161566494P | 2011-12-02 | 2011-12-02 | |
| US61/566,494 | 2011-12-02 | ||
| PCT/US2012/066984 WO2013082241A2 (en) | 2011-12-02 | 2012-11-29 | Improved methods of treating ischemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017041708A Division JP6415616B2 (ja) | 2011-12-02 | 2017-03-06 | 虚血を処置する改善された方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505829A JP2015505829A (ja) | 2015-02-26 |
| JP2015505829A5 true JP2015505829A5 (cg-RX-API-DMAC7.html) | 2016-01-28 |
| JP6106688B2 JP6106688B2 (ja) | 2017-04-05 |
Family
ID=48536234
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014544867A Active JP6106688B2 (ja) | 2011-12-02 | 2012-11-29 | 虚血を処置する改善された方法 |
| JP2017041708A Active JP6415616B2 (ja) | 2011-12-02 | 2017-03-06 | 虚血を処置する改善された方法 |
| JP2018153543A Active JP6727261B2 (ja) | 2011-12-02 | 2018-08-17 | 虚血を処置する改善された方法 |
| JP2020112693A Withdrawn JP2020158540A (ja) | 2011-12-02 | 2020-06-30 | 虚血を処置する改善された方法 |
| JP2022070033A Pending JP2022093428A (ja) | 2011-12-02 | 2022-04-21 | 虚血を処置する改善された方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017041708A Active JP6415616B2 (ja) | 2011-12-02 | 2017-03-06 | 虚血を処置する改善された方法 |
| JP2018153543A Active JP6727261B2 (ja) | 2011-12-02 | 2018-08-17 | 虚血を処置する改善された方法 |
| JP2020112693A Withdrawn JP2020158540A (ja) | 2011-12-02 | 2020-06-30 | 虚血を処置する改善された方法 |
| JP2022070033A Pending JP2022093428A (ja) | 2011-12-02 | 2022-04-21 | 虚血を処置する改善された方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10111907B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3381456A1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP6106688B2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2682255T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013082241A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3785767A1 (en) | 2011-12-02 | 2021-03-03 | Fate Therapeutics, Inc. | Enhanced stem cell composition |
| ES2682255T3 (es) * | 2011-12-02 | 2018-09-19 | Fate Therapeutics, Inc. | Métodos mejorados de tratamiento de isquemia |
| US20150328249A1 (en) * | 2012-12-11 | 2015-11-19 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Modulation of myofiber repair by anti-myostatin strategies and/or ppar gamma ligands, alone or in combination with stem cells, for the therapy of critical limb ischemia and other ischemic processes affecting the skeletal muscle |
| WO2014150602A1 (en) * | 2013-03-15 | 2014-09-25 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
| US9943545B2 (en) | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
| KR101674253B1 (ko) * | 2014-07-16 | 2016-11-08 | 연세대학교 산학협력단 | 트랜스웰 및 케모카인을 이용한 줄기세포의 분리 방법 |
| US20190119635A1 (en) * | 2015-05-05 | 2019-04-25 | Fate Therapeutics, Inc. | Modulation of t lymphocytes |
| JP2018520688A (ja) | 2015-07-21 | 2018-08-02 | ザ チルドレンズ メディカル センター コーポレーション | Ｐｄ−ｌ１発現造血幹細胞およびその使用 |
| KR20170020273A (ko) * | 2015-08-12 | 2017-02-22 | (주)차바이오텍 | 향상된 탯줄 유래 부착형 줄기세포, 그의 제조방법 및 용도 |
| WO2017026838A1 (ko) * | 2015-08-12 | 2017-02-16 | 주식회사 차바이오텍 | 향상된 탯줄 유래 부착형 줄기세포, 그의 제조방법 및 용도 |
| EP3349725A1 (en) * | 2015-09-16 | 2018-07-25 | Centre National de la Recherche Scientifique (CNRS) | Gelling compositions for treating malignant tumours and/or preventing tumour recurrence |
| CN109072186B (zh) * | 2016-03-04 | 2023-06-23 | 莱兰斯坦福初级大学评议会 | 利用前列腺素e2进行肌肉再生的组合物和方法 |
| US9918994B2 (en) * | 2016-03-04 | 2018-03-20 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for muscle regeneration using prostaglandin E2 |
| KR102002671B1 (ko) * | 2016-11-11 | 2019-07-23 | 사회복지법인 삼성생명공익재단 | 2ｄｇ를 이용한 줄기세포 역량 향상 방법 |
| KR102698911B1 (ko) | 2017-06-09 | 2024-08-23 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 근육 질환을 예방하거나 치료하기 위한 조성물 및 방법 |
| US11879137B2 (en) | 2017-09-22 | 2024-01-23 | The Children's Medical Center Corporation | Treatment of type 1 diabetes and autoimmune diseases or disorders |
| WO2019102761A1 (ja) | 2017-11-24 | 2019-05-31 | Ｋｙｂ株式会社 | 筒型リニアモータ |
| GB202211232D0 (en) | 2022-08-02 | 2022-09-14 | Heptares Therapeutics Ltd | Prostaglandin EP4 receptor agonist compounds |
| CN116966302B (zh) * | 2023-06-28 | 2025-11-25 | 华中科技大学同济医学院附属协和医院 | Areg的新用途 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5420033A (en) | 1989-06-21 | 1995-05-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Epithelial cell line expressing a cystic fibrosis phenotype |
| US5077049A (en) | 1989-07-24 | 1991-12-31 | Vipont Pharmaceutical, Inc. | Biodegradable system for regenerating the periodontium |
| SG43009A1 (en) | 1989-10-16 | 1997-10-17 | Amgen Inc | Stem cell factor |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
| CA2123094C (en) | 1991-11-06 | 1999-08-10 | Paulo N. Correa | Cell culture medium |
| US5460964A (en) | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
| US5442033A (en) | 1993-07-20 | 1995-08-15 | Ethicon, Inc. | Liquid copolymers of epsilon-caprolactone and lactide |
| SG52619A1 (en) | 1993-08-23 | 1998-09-28 | Baxter Int | In vitro growth of neutrophil and megakaryocte precursors in serum-free media |
| US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
| US5648331A (en) | 1994-08-26 | 1997-07-15 | G.D. Searle & Co. | Method of inhibiting tissue ischemia and reperfusion injury |
| US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
| US5753516A (en) | 1995-02-03 | 1998-05-19 | Heagy; Wyrta E. | Screening method for ligands of the EBI-1 receptor |
| AU6125396A (en) | 1995-06-07 | 1996-12-30 | Novartis Ag | Serum-free media for primitive hematopoietic cells and metho ds of use thereof |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US5945337A (en) | 1996-10-18 | 1999-08-31 | Quality Biological, Inc. | Method for culturing CD34+ cells in a serum-free medium |
| US6372796B1 (en) | 1996-11-13 | 2002-04-16 | Cold Spring Harbor Laboratory | Therapeutic uses for nitric oxide inhibitors |
| US6191109B1 (en) | 1997-10-31 | 2001-02-20 | Children's Hospital, Inc. | Methods of treating intestinal ischemia using heparin-binding epidermal growth factor |
| WO2000038663A2 (en) | 1998-12-24 | 2000-07-06 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
| GB9904281D0 (en) | 1999-02-24 | 1999-04-21 | Reneuron Ltd | Transplantation |
| WO2001012596A1 (fr) | 1999-08-13 | 2001-02-22 | Taisho Pharmaceutical Co., Ltd. | Derives de prostaglandine |
| TWI247606B (en) | 1999-11-24 | 2006-01-21 | Ono Pharmaceutical Co | Treating agent for osteopenic diseases |
| BR0015781A (pt) | 1999-11-24 | 2002-12-31 | Ono Pharmaceutical Co | Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea |
| DK1132086T3 (da) | 2000-01-31 | 2006-08-28 | Pfizer Prod Inc | Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| FR2825261B1 (fr) | 2001-06-01 | 2003-09-12 | Maco Pharma Sa | Ligne de prelevement du sang placentaire comprenant une poche de rincage |
| US7179643B2 (en) | 2001-06-14 | 2007-02-20 | Reliance Life Sciences Pvt. Ltd. | Device and a process for expansion of haemopoeitic stem cells for therapeutic use |
| EP1458854B1 (en) | 2001-12-21 | 2010-04-14 | Mount Sinai Hospital | Cellular compositions and methods of making and using them |
| AU2003272963A1 (en) | 2002-10-10 | 2004-05-04 | Ono Pharmaceutical Co., Ltd. | Endogenous repair factor production promoters |
| EP1601351A1 (en) | 2003-03-04 | 2005-12-07 | Pfizer Products Inc. | Use of ep2 selective receptor agonists in medical treatment |
| AU2004217699B2 (en) | 2003-03-07 | 2008-07-03 | Gamida-Cell Ltd. | Expansion of renewable stem cell populations using modulators of PI 3-kinase |
| WO2004081196A2 (en) | 2003-03-11 | 2004-09-23 | Qlt Usa Inc. | Formulations for cell- schedule dependent anticancer agents |
| US6747037B1 (en) | 2003-06-06 | 2004-06-08 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| US8309608B2 (en) | 2003-11-06 | 2012-11-13 | Sanofi-Aventis Deutschland Gmbh | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases |
| EP1701729B1 (en) | 2003-12-31 | 2018-05-02 | Warsaw Orthopedic, Inc. | Improved bone matrix compositions and methods |
| JP4086816B2 (ja) | 2004-07-01 | 2008-05-14 | 株式会社Ｎｅｃ情報システムズ | Ｂｇａ部品搭載基板の層数見積もり装置及び方法並びに層数見積もりプログラム |
| US7147626B2 (en) | 2004-09-23 | 2006-12-12 | Celgene Corporation | Cord blood and placenta collection kit |
| AU2005287855B2 (en) | 2004-09-24 | 2011-06-16 | Mesoblast, Inc. | Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC) |
| AU2005299473B2 (en) | 2004-10-26 | 2012-06-28 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin EP4 agonists |
| WO2006078886A2 (en) | 2005-01-18 | 2006-07-27 | Irm Llc | Compounds and compositions as wnt signaling pathway modulators |
| WO2006086639A1 (en) | 2005-02-10 | 2006-08-17 | Regents Of The University Of Minnesota | Vascular/lymphatic endothelial cells |
| AU2006311637A1 (en) | 2005-11-07 | 2007-05-18 | The General Hospital Corporation | Methods and compositions for modulation of stem cell aging |
| US8318489B2 (en) | 2005-12-22 | 2012-11-27 | Bruce Paul Davidson | Prostacyclin directed differentiation of cardiomyocytes from human embryonic stem cells |
| DE102005062741A1 (de) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Fluorene und Carbazole als Liganden des EP2 Rezeptors |
| JP5247675B2 (ja) | 2006-03-24 | 2013-07-24 | チルドレンズ メディカル センター コーポレーション | 造血性幹細胞の増殖を調節する方法 |
| WO2008021475A2 (en) | 2006-08-16 | 2008-02-21 | The General Hospital Corporation | Compositions and methods for hematopoietic stem cell expansion or for modulating angiogenesis |
| WO2008056963A1 (en) | 2006-11-10 | 2008-05-15 | Chanil Moon | Method for proliferating stem cells with leptin |
| WO2008073748A1 (en) | 2006-12-08 | 2008-06-19 | University Of Rochester | Expansion of hematopoietic stem cells |
| US8871752B2 (en) | 2008-02-19 | 2014-10-28 | Sucampo Ag | Method for modulating stem cell growth |
| US20110165128A1 (en) | 2008-03-07 | 2011-07-07 | Columbia University In The City Of New York | Homing in mesenchymal stem cells |
| US8092822B2 (en) | 2008-09-29 | 2012-01-10 | Abbott Cardiovascular Systems Inc. | Coatings including dexamethasone derivatives and analogs and olimus drugs |
| ES2845641T3 (es) * | 2008-11-06 | 2021-07-27 | Univ Indiana Res & Tech Corp | Materiales y métodos para mejorar procedimientos de injerto funcionante de células madre hematopoyéticas |
| JP5705127B2 (ja) | 2008-12-03 | 2015-04-22 | アモーサイト インコーポレイテッド | 梗塞領域灌流改善組成物および血管損傷修復の方法 |
| WO2010108028A2 (en) | 2009-03-19 | 2010-09-23 | Fate Therapeutics, Inc. | Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same |
| WO2011060381A1 (en) | 2009-11-15 | 2011-05-19 | Indiana University Research & Technology Corporation | Methods to enhance delivery and engraftment of stem cells including the identification of specific prostagandin e2 receptors |
| BR112013003366A2 (pt) | 2010-08-12 | 2020-08-04 | Fate Therapeutics, Inc. | terapia aperfeiçoada de células tronco hematopoiéticas e progenitoras |
| ES2682255T3 (es) * | 2011-12-02 | 2018-09-19 | Fate Therapeutics, Inc. | Métodos mejorados de tratamiento de isquemia |
| EP3785767A1 (en) | 2011-12-02 | 2021-03-03 | Fate Therapeutics, Inc. | Enhanced stem cell composition |
-
2012
- 2012-11-29 ES ES12852924.5T patent/ES2682255T3/es active Active
- 2012-11-29 WO PCT/US2012/066984 patent/WO2013082241A2/en not_active Ceased
- 2012-11-29 EP EP18169424.1A patent/EP3381456A1/en not_active Withdrawn
- 2012-11-29 EP EP12852924.5A patent/EP2785350B1/en active Active
- 2012-11-29 US US14/362,385 patent/US10111907B2/en active Active
- 2012-11-29 JP JP2014544867A patent/JP6106688B2/ja active Active
-
2017
- 2017-03-06 JP JP2017041708A patent/JP6415616B2/ja active Active
-
2018
- 2018-08-17 JP JP2018153543A patent/JP6727261B2/ja active Active
- 2018-09-19 US US16/135,889 patent/US10980838B2/en active Active
-
2020
- 2020-06-30 JP JP2020112693A patent/JP2020158540A/ja not_active Withdrawn
-
2021
- 2021-04-12 US US17/228,128 patent/US20220054553A1/en not_active Abandoned
-
2022
- 2022-04-21 JP JP2022070033A patent/JP2022093428A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505829A5 (cg-RX-API-DMAC7.html) | ||
| JP2015504313A5 (cg-RX-API-DMAC7.html) | ||
| Li et al. | Mechanism and application of exosomes in the wound healing process in diabetes mellitus | |
| JP6415616B2 (ja) | 虚血を処置する改善された方法 | |
| JP6483187B2 (ja) | 増強された幹細胞組成物 | |
| Chen et al. | Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets | |
| Krampera et al. | Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy | |
| US10702556B2 (en) | Compositions and methods for inducing angiogenesis | |
| Volpe et al. | Efficacy of cord blood platelet gel application for enhancing diabetic foot ulcer healing after lower limb revascularization | |
| US10383895B2 (en) | Stimulation of therapeutic angiogenesis by T regulatory cells | |
| CN107073083A (zh) | 用于从自体生理流体产生增强的抗炎/抗分解代谢剂和再生剂的方法和组合物 | |
| Tracy et al. | State of the field: cellular and exosomal therapeutic approaches in vascular regeneration | |
| Dong et al. | Recent advances in adipose-derived mesenchymal stem cell-derived exosomes for regulating macrophage polarization | |
| Assar et al. | Improvement in the clinical manifestations of interstitial lung disease following treatment with Placental Mesenchymal Stromal cell extracellular Vesicles in A patient with systemic sclerosis: A case report | |
| Dorofeeva et al. | Efficacy of various combined treatment regimens in patients with stable effort angina, functional classes II-III | |
| Ricart et al. | Cell therapies for IBD: what works? | |
| Dabravolski et al. | Preclinical and mechanistic perspectives on adipose-derived stem cells for atherosclerotic cardiovascular disease treatment | |
| Tonkin et al. | Healing the ischaemic heart: a critical review of stem cell therapies | |
| US12145984B2 (en) | Methods for preventing ischemia reperfusion injury in an organ with antibody antagonists of IL-33 | |
| Lee et al. | Muslin-induced intracranial vasculopathic stenosis: a report of two cases | |
| RU2649498C1 (ru) | Способ лечения ишемической ангиопатии сосудов нижних конечностей | |
| Bhat et al. | From Trials to Therapeutics: are Mesenchymal Stem Cells Promising in Cellular Therapy? | |
| LeBlanc | State of the Field: Cellular and Exosomal Therapeutic Approaches in Vascular Regeneration 2 | |
| Winger et al. | Part C: Immune Treatments: Recent Developments | |
| CN111491640A (zh) | 包含葡聚糖或泊咯沙姆的用于治疗关节疾病或结缔组织病的组合物 |